InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Telix Pharmaceuticals Ltd

TLX Clue Score72
Australia Fiscal year ends December CIK 0002007191
$11.21 +1.82% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $11.21 +11.10% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 14 Nov 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2022Revenue160.1Operating income−91.9Net income−104.1EPS, diluted−33.50Fiscal year 2023Revenue502.5 +213.9%Operating income15.8Net income5.2EPS, diluted1.61Fiscal year 2024Revenue783.2 +55.8%Operating income82.1Net income49.9 +858.0%EPS, diluted14.46 +798.1%Fiscal year 2025
FY2022FY2023FY2024FY2025
Revenue 160.1 502.5 783.2 n/a
Growth +213.9% +55.8%
Operating income −91.9 15.8 82.1 n/a
Net income −104.1 5.2 49.9 n/a
Growth +858.0%
EPS, diluted −33.50 1.61 14.46 n/a
Growth +798.1%

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2022Gross margin59.3%Operating margin−57.4%Net margin−65.0%Free cash flow margin−44.4%Fiscal year 2023Gross margin62.6%Operating margin3.2%Net margin1.0%Free cash flow margin2.8%Fiscal year 2024Gross margin65.1%Operating margin10.5%Net margin6.4%Free cash flow margin3.7%Fiscal year 2025
FY2022FY2023FY2024FY2025
Gross margin 59.3% 62.6% 65.1% n/a
Operating margin −57.4% 3.2% 10.5% n/a
Net margin −65.0% 1.0% 6.4% n/a
Free cash flow margin −44.4% 2.8% 3.7% n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−64.0Capital expenditure−7.0Free cash flow−71.0Fiscal year 2023Operating cash flow23.9Capital expenditure−9.7Free cash flow14.2Fiscal year 2024Operating cash flow43.0Capital expenditure−14.3Free cash flow28.7 +102.1%Fiscal year 2025
FY2022FY2023FY2024FY2025
Operating cash flow −64.0 23.9 43.0 n/a
Capital expenditure −7.0 −9.7 −14.3 n/a
Free cash flow −71.0 14.2 28.7 n/a
Growth +102.1%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2022Cash116.3Shareholders’ equity80.0Fiscal year 2023Cash123.2Total debt5.9Net cash (debt)117.3Shareholders’ equity148.9Debt to equity0.04Fiscal year 2024Cash710.3Total debt341.8Net cash (debt)368.5Shareholders’ equity568.2Debt to equity0.60Fiscal year 2025Total debt391.9
FY2022FY2023FY2024FY2025
Cash 116.3 123.2 710.3 n/a
Total debt n/a 5.9 341.8 391.9
Net cash (debt) n/a 117.3 368.5 n/a
Shareholders’ equity 80.0 148.9 568.2 n/a
Debt to equity n/a 0.04 0.60 n/a

In millions of AUD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of AUD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
160.1 502.5 783.2 n/a
Growth +213.9% +55.8%
65.2 188.2 273.5 n/a
94.9 314.4 509.7 n/a
Growth +231.2% +62.1%
80.7 128.5 194.6 n/a
47.2 74.2 129.8 n/a
−91.9 15.8 82.1 n/a
Growth +418.5%
−98.6 3.1 56.1 n/a
5.5 −2.1 6.1 n/a
−104.1 5.2 49.9 n/a
Growth +858.0%
Per share
−33.50 1.63 15.07 n/a
−33.50 1.61 14.46 n/a
Growth +798.1%
310.6 319.2 331.2 337.9
310.6 323.7 345.2 337.9
Growth +4.2% +6.6% −2.1%

Shown in AUD as filed; the screener converts to dollars.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 1 of 3 years on file.